Market Forecast
Meningococcal Vaccines Market has a demand for USD 172 Million doses in 2019. Further, the global estimated supply in 2019 is expected to be 203 Million doses.
Market Synopsis
Meningococcal meningitis is a bacterial infection caused by Neisseria meningitides. Disease incidence is high in West and Central Africa, where historically, serogroup A has been the most important cause of disease. More recently, meningitis outbreaks have gradually been associated with serogroup C, and to a lesser extent, serogroup W.
The meningococcal vaccines market is complex and diverse, with regional variations in serogroup distribution with substantial use outside routine immunization. The vaccine has approximately 29 marketed products targeting various combinations of the six serogroups (A, B, C, W, X, Y).
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8622
Market Influencer
Without an increase in production, the existing supply of conjugate MenACWY will be inadequate to meet the demand generated by the rising incidence of serogroups C and W, and the low availability of polysaccharide vaccines. Further, several multivalent, conjugate vaccines by Chinese and Indian manufacturers are in the pipeline, and, if prequalified they will be registered for use in many geographies. Moreover, if they are made available at acceptable prices it could increase global demand in Meningococcal Vaccines Market Trends.
Market Drivers
- Rise in prevalence of the meningococcal disease
- According to a document published by the U.S. Department of Health & Human Services, in 2017, there were approximately 350 cases of meningococcal disease reported. The disease has an incidence rate of 0.11 cases per 100,000 people in the United States. Any population group can be affected by the disease, with maximum prevalence in children younger than one-year-old and a second peak in adolescence. Adolescents and young adults, ranging from 16 to 23 years old, have the highest rates of meningococcal disease.
- Further, increasing incidence of meningococcal disease in West and Central Africa regions is expected to drive the demand in the African region
- Booming mortality of the meningococcal disease is leading to increasing demand for the vaccines
- Approximately 10 to 15 in 100 people affected with meningococcal disease will face mortality. Further, up to 1 in 5 survivors will have long-term disabilities, such as loss of limb, deafness, and damage to the nervous system brain among others
- Escalating positive results with the vaccines to boost the demand in the market
- Growing research and development activities by prominent players in the industry
Market Restraints
- Withdrawn production of polysaccharide vaccines has resulted in reduced country access, particularly for MICs in various regions. For example, Sanofi Pasteur, manufacturer of Menomune, declared in 2017 that the company is discontinuing the production of the vaccine. With the production of Menomune at hold, there were no polysaccharide vaccines approved for use in the United States
Meningococcal Vaccines Market Segmentation
By treatment, the market is segmented into Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine.
Meningococcal A conjugate vaccine is significantly used in mass campaigns across affected regions like Africa. Since 2010, the vaccine has significantly decreased meningococcal disease incidence in the region. However, the demand for meningococcal A conjugate in the country remains uncertain given that national immunization program adoptions are based on the timing of Gavi funding decisions, the country’s readiness, and competing for vaccine introduction priorities.
In the polysaccharide segment, products such as MenACWY vaccines are in high demand. MenACWY vaccine is the most desirable combination, given its broader serotype coverage. MenACWY specifically has nine products that are available across polysaccharide and conjugate product segments, but conjugate products are suggested for use in routine immunization activities.
Moreover, the demand and supply of Subcap MenB vaccines is restricted to HICs and influenced by their acceptance into NIPs. Improved uptake of MenB vaccines is expected in the coming years but will likely be moderate and limited to high-income markets given the high price and competing interest of introducing MenACWY conjugate.
By end-user, the market is segmented into Hospital & Clinical, Research Laboratories, and Academic Institutes
Hospitals and clinics control the global market for meningococcal vaccines. The high growth of hospitals and clinics segment is attributed to the increasing application of vaccines in these healthcare facilities in conjunction with the growing prevalence and incidence of the meningococcal disease.
Moreover, research laboratories and academic institutes take up the second-largest share due to the boost in research and development in the market.
By region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
In the global market, China is expected to have the largest market share, which accounts for approximately 35% of the global demand. This is primarily due to polysaccharide products, which currently comprise 84% of China’s demand. Chinese suppliers presently focus only on meeting the demand of the domestic market, but some of the manufacturers have indicated interest in the global market as well. The dynamic product pipeline with several multivalent conjugate products in development may trigger changes in the future supply mix of the Chinese market. Moreover, in China, non-routine use (excluding campaigns) accounts for an estimated 9 million doses in 2019, which may help to sustain the huge market share in the forecast period.
UNICEF foresees all 26 African countries in the meningitis belt, which have completed mass campaigns in 2016. In 2015, seven countries in the region were introduced with meningococcal A conjugate vaccine through their mass campaigns and targeted a population of 233 million. Further, during 2016-2018, UNICEF introduced meningococcal A conjugate vaccine in 26 countries. Ghana was the first country to be introduced with the vaccine into its RI schedule in 2016. Also, four other countries including Mali, Niger, Nigeria, and Sudan introduced the vaccine into RI programs in 2016.
Key Developments in the Global Meningococcal Vaccines Market
- In 2018, Pfizer granted FDA Breakthrough Therapy designation for Trumenba (Meningococcal Group B Vaccine). This vaccine plays a major role in the prevention of invasive meningococcal B disease in children aged 1 to 9 years
- In 2018, GSK’s meningitis B vaccine Bexsero received Breakthrough Therapy designation from the US FDA for prevention of Invasive Meningococcal Disease for children 2-10 years of age
- In 2015, Novartis Bexsero vaccine was approved by the FDA for the prevention of meningitis B. This vaccine is used as active immunization to prevent invasive meningococcal disease caused by serogroup B
Key Players
- Baxter international
- Pfizer Inc.
- Sanofi S.A.
- Novartis Pharmaceuticals Inc.
- JN-International Medical Corporation
- Serum Institute of India Ltd.
- GlaxoSmithKline
- BIO-MED
- Others
Browse more Details of the Report @
https://www.marketresearchfuture.com/reports/meningococcal-vaccines-market-8622
Pediatric Vaccines Market Research Report: Information by Type (Monovalent Vaccines and Multivalent Vaccines), Technology (Live Attenuated, Inactivated, Subunits, Toxoids, Conjugates and others), Application (Polio, Diphtheria-Tetanus-Acellular Pertussis, Haemophilus Influenzae type B, MMR, Hepatitis B, Pneumococcal Vaccine and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Global Forecast till 2025Segmentation Analysis:The Global Pediatric Vaccines Market Segmented on the basis of type, technology, disease indication, and route of administration.
On the basis of type, the global pediatric vaccines market is segmented into monovalent vaccines, multivalent vaccines, and others.On the basis of technology, the global pediatric vaccines market is segmented into synthetic vaccines, dendritic cells vaccines, conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, and others.On the basis of disease indication, the global pediatric vaccines market is segmented into MMR (Measles, Mumps, and Rubella), polio, Haemophilus influenza type B, pneumococcal disease, meningococcal disease, influenza, DTP (Diphtheria, Tetanus, Pertussis), hepatitis, varicella, rotavirus, combination vaccines and others.
On the basis of route of administration, the global pediatric vaccines market is segmented into intramuscular administration, subcutaneous administration, oral administration, and other routes of administrationPediatric Vaccines Market AnalysisThere has been constant research for the development of novel molecules providing immunity against fatal diseases such as Zika virus and different types of cancers.
The vaccines administered to prevent children from several non-infectious and infectious diseases are known as pediatric vaccines.
Thus, they assist the immune system in protecting itself from infectious or non-infectious diseases in the future.
There are different pediatric vaccines accessible in the market, for example, pneumococcal immunization, polio antibody, rotavirus immunization, MMR immunization, flu immunization, hepatitis B antibody, meningococcal immunization, and Hib antibody.However, low accessibility to remote areas, increasing availability of biosimilars at low rates, increasing cost of vaccines, limited or no access to healthcare services in developing and under-developed countries, low healthcare spending, and less medical coverage for pediatric vaccination are some of the challenges which might hamper the growth of the global pediatric vaccines market in future.Key Players: Some of the key players in the global pediatric vaccines market are GlaxoSmithKline plc (U.K.), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), Sanofi Pasteur SA (France), Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Serum Institute of India Pvt.
Increasing incidence of TB cases worldwide, technological advancements in vaccine discovery and developments, and implementation of favorable government policies are some key factors driving market growthReports and Data has recently published a new research report on Global BCG Vaccine Market that covers current development scenario and emerging trends of the market.
The research report provides a comprehensive assessment of the market size, market share, revenue growth, and provides a futuristic perspective about the market trends, growth factors, facts, and industry validated market data.
The report applies advanced statistical tools such as Porter’s Five Forces analysis and SWOT analysis to shed light on the competitive landscape of the global BCG Vaccine market.
The report covers all the critical and essential information relating to the global BCG Vaccine market which helps the readers and clients gain a thorough understanding of the market.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/30The report initially offers market introduction, market overview, product scope, market opportunities, growth prospects, risks, limitations, and key drivers.
The report also covers a comprehensive analysis of the competitive landscape with extensive profiling of the key competitors.
It covers recent technological advancements, product developments, product launches, mergers and acquisitions, collaborations, joint ventures, and partnerships.Key Companies in the market include:Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt.
Global Hidradenitis Suppurativa Market information, by skin conditions (pimples, folliculitis, deep-acne like cysts and blackheads, boils, and and others), by treatment (medications, surgery, and others), by end user- Forecast till 2023Hidradenitis Suppurativa Market ScenarioMarket Research Future (MRFR) speculates that the global hidradenitis suppurativa market size is predicted to garner USD 763.6 million, grabbing a CAGR of 4.2% during the forecast period (2017-2023).
It generally occurs between 20 to 40 years of age and is three times common among the women population than in the male population.
It is a dermatological disease affecting the areas of apocrine sweat glands like the area under the breast, buttocks, inner the thighs, and under the arms.
Early symptoms involve local hidradenitis and erythema, which become painful in the later stages.Hidradenitis Suppurativa Market Potential and PitfallsWith augmenting incidences of several skin diseases, the global hidradenitis suppurativa market is likely to flourish.
Moreover, with rapid urbanization and rising population coupled with the improving economic condition, the quality of healthcare is rising, which is further offering an impetus to the hidradenitis suppurativa market across the market.On the contrary, the high cost of treatment and unmet medical needs and drug resistance are some of the top barriers considered to disrupt the market growth to a great extent.
Among these, surgical removal is considered as a preferred mode of treatment, but the disease might relapse into other areas as well.By mode of end-user, the global hidradenitis suppurativa market has been segmented into dermatology clinics, hospitals, academic institutes, medical research centers, and others.Hidradenitis Suppurativa Market Regional AnalysisGeographically, the hidradenitis suppurativa market span across regions namely, North America, Asia Pacific, Europe, and the Middle East & Africa.Among all the regions, the North American region is predicted to lead the global hidradenitis suppurativa market with the largest share.
Global Non Clinical Information System Market Information by Applications (Hospitals, Clinics, Laboratories and Ambulatory care solutions), by Components (Service, Software, Hardware), and Deployment (Web-based, Cloud-based, On-premise) - Forecast to 2027Market overviewNon Clinical Information System Market Application is a hospital information system that helps to manage, store and check the detailed information related to healthcare such as prescriptions, health history of patients, and another comment that is special where all other information is kept together electronically.
Non Clinical Information System Market Growth is forecasted to reach at highest CAGR by 2027.The recent report on Non Clinical Information System Market Application market predicts the industry’s performance for the upcoming years to help stakeholders in making the right decisions those right decisions that can potentially garner strong returns.
Application segmentation can be classified into hospitals, clinics, laboratories, ambulatory care solutions, and much more.
The high adoption rate in non-clinical systems by laboratories, clinics, & hospitals can support growth of Non Clinical Information System Market Dynamics.
The market of non-clinical system appears to be highly competitive.
In order to maintain their market position and to drive Non Clinical Information System Market Growth, various dynamic and diversified international organizations, domestic organizations, and as well as new entrants form a competitive landscape are required.Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/761Market segmentationAs per Non Clinical Information System Market Analysis, this market is divided into different parts like end-user, application, component, and region.
